Trastuzumab was first approved in 1998 and has been widely used for the treatment of HER2-postive breast cancer and gastric cancer, while pertuzumab was approved in 2012 and has been used to treat HER2-positive breast cancer (Baselga et al., 2012) since 2012. Here, ERBB2 is linked to breast carcinoma.